ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and DuChemBio Co, Ltd. (DCB), a leading Korean radiopharmaceutical company, recently announced the conclusion of an exclusive licensing and development agreement for Solucin®Targeted Radionuclide Therapy (TRT) in South Korea. The agreement sets out terms concerning the local development, registration and subsequent commercialization by DCB of ITM’s proprietary brand Solucin®for Targeted Radionuclide Therapy (TRT) in South Korea. Solucin®patient doses will be manufactured and exclusively supplied to DCB by ITM.
Within the framework of this collaboration, DCB and ITM plan to initiate a local clinical study for ITM’s Solucin®TRT which is expected to begin recruiting patients in 2020. The study concept is based on ITM’s Phase III clinical trial COMPETE, which has recently seen a considerable increase in patients as a result of strong recruitment in the United States in particular. COMPETE involves 42 leading cancer centers in 12 countries, predominantly in Europe, North America, South Africa and Australia.
Full Press Release
Within the framework of this collaboration, DCB and ITM plan to initiate a local clinical study for ITM’s Solucin®TRT which is expected to begin recruiting patients in 2020. The study concept is based on ITM’s Phase III clinical trial COMPETE, which has recently seen a considerable increase in patients as a result of strong recruitment in the United States in particular. COMPETE involves 42 leading cancer centers in 12 countries, predominantly in Europe, North America, South Africa and Australia.
Full Press Release